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In the preceding paper (1),  we reported a  significant striking association between 
Dw2 and IgE and IgG antibody (Ab) 1 responses to Ra5 in ragweed-allergic Caucasian 
subjects as a  result of natural exposure to ragweed pollen.  The question  arose as to 
whether  this  relationship  might  change  after parenteral  immunization  with  much 
higher  dosages of ragweed  antigens.  Such  treatment,  known  as  immunotherapy or 
hyposensitization, is commonly administered to ragweed-allergic patients to alleviate 
their  allergic  symptoms (2).  Effective treatment  is  normally accompanied  by high 
levels of serum IgG Ab toward ragweed antigens, especially the principal component, 
antigen E  (AGE)  (3). 
Whereas the adult dosage of inhaled Ra5 is probably no more than 60 ng over the 
8-wk period of ragweed pollination  (4),  cumulative annual  immunotherapeutic dos- 
ages of Ra5 are usually at least one or two orders of magnitude higher. We will show 
that  such  immunotherapy induces  good  immunoglobulin  G  (IgG)  Ab  responses to 
Ra5  in  all  ragweed-allergic  individuals  who  possess  Dw2,  whether  or  not  they 
produced  IgE and/or  IgG Ab  to  Ra5  before therapy,  whereas  the  prevalence and 
level of IgG Ab response in  persons lacking Dw2 are both much lower.  Despite an 
extreme  degree  of heterogeneity  in  the  type  of therapy  and  antigen  dosage,  the 
association between IgG Ab response to Ra5 and Dw2 becomes increasingly stronger 
and more significant over a  3-yr period of therapy. 
Materials and Methods 
Patients.  The study group was comprised of 61 highly ragweed-allergic  patients, who were 
a  subset  of the  86  patients  included  in  the  "clinic group,"  in  the preceding paper (1). As 
previously stated,  there  was  a  bias  toward  selecting  Ra5  responders,  and,  therefore,  the 
proportion of Ra5+ subjects  (23%) was higher than the value of ~9% one might expect in a 
random sample of ragweed-allergic  subjects  (cf. data for Westinghouse  study group in ref.  1). 
* Supported by grants AI-13370 and AI-10304 from the National Institutes of  Health. This is publication 
463 from the O'Neill Laboratories of the Good Samaritan Hospital. 
I Abbreviations used in this paper."  Ab, antibody; BSA, bovine serum albumin; BBS, borate-buffered  saline, 
pH 8.3; CIE, crossed immunoelectrophoresis;  Creg, cross-reacting group (of HLA antigens);  DNV, double- 
normalized  values;  Dw2+(-),  positive  (negative)  for  HLA  specificity  Dw2;  HLA,  human  leukocyte 
antigen; HSA, human serum albumin; Ra5+(-), positive  (negative)  response to Ra5;  RIA, radioimmu- 
noassay. 
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TABLE  I 
Numbers of Available Post-Treatment Serum Samples and Dosages of Antigens for the First 3 yr of Therapy 
Year l  Year 2  Year 3 
Number  of  patients  receiving  aqueous 
ragweed extract* 
Cumulative  dosages,  geometric  mean 
(range) in #g Ra5 equivalents:[: 
Final dosages,  geometric mean (range) 
in/~g Ra5 equivalents$ 
Number of patients receiving aqueous 
allergoid* 
Cumulative  dosages,  geometric  mean 
(range) in/~g Ra5 equivalents§ 
Final dosages,  geometric mean (range) 
in/tg Ra5 equivalents§ 
Number of patients receiving alum-rag- 
weed* 
20  16  5 
0.75 0.06--60)  1.4 (0.18--9.9)  8.7 (4.1--12) 
0.14 (0.01--12)  0.26 (0.08--0.68)  0.37  (0.12--0.54) 
32  27  28 
14 (0.53--101)  26 (0.56--695)  24 (1.5--599) 
3.9 (0.12--68)  4.2 (0.09--28)  4.7 (0.46--28) 
9  7  7 
Total number of patients  61  50  40[[ 
* The changes in the numbers of serum samples in successive years reflect  patients switching treatment to 
a different antigen as well as patients who dropped out of the study. 
:[: Cumulative and final dosages of AgE averaged 8.4-fold  higher than those of Ra5. 
§ Cumulative and final dosages of AgE averaged 16.7-fold higher than those of Ra5. 
[[ These 40 individuals received therapy during years 1, 2, and 3, and serum samples were available for all 
3 yr. Note that subjects J. G. (Fig.  1 b) and W. R. (Fig. 2 b) were not included because of an incomplete 
set of serum samples. 
Pre- and post-treatment serum samples for each year of therapy were available on almost all of 
the patients. The sera had been stored at -20 ° or -70°C  between the period of collection and 
analysis of serum Ab levels. 
All 61  individuals had received  immunotherapy with ragweed pollen antigens for periods 
ranging  from  1-9  yr,  either preseasonally  (every  2-4  wk  for  12-16  wk  before  the  ragweed 
season)  (5) 2 or on a  perennial basis  (every  1-2 wk  except  during the ragweed  pollen season, 
approximately August  15 to October 15 (6, 7). In either mode of therapy, antigen dosages were 
built  up  gradually  from  low  levels,  depending  on  the  patient's  tolerance  to  the  injections. 
Therefore, antigen dosages varied considerably from patient to patient, as summarized for the 
first 3 yr of treatment in Table I. Three different types of antigen were used: aqueous ragweed 
pollen extract  (5-7),  2 formaldehyde-modified ragweed  ("allergoid;" 5-7),  2 and alum-precipi- 
tated ragweed  (6). Two of the antigens were well standardized as far as their content of Ra5 
and AgE. Reliable standardization could not be performed for the alum-precipitated material, 
which was used in a  few patients. 
Different  types  of antigen  and  varying  antigen  dosages  were  administered,  and  certain 
patients switched from one antigen to another, depending on the goal of the particular study 
in which the patient was a  participant. Because several patients dropped out of the studies, the 
total number of patients for whom post-treatment serum samples were available decreased each 
year (Table I). A  complete set of pre- and post-treatment sera were,  however, available on a 
subgroup of 40 patients who had been treated for 3 successive yr from the start of therapy. 
Antigens and Assays  for Ab and Total IgE.  The Ra5 preparation and radioimmunoassays (RIA) 
of IgG Ab and IgE Ab responses to Ra5 were as described in the preceding paper (1). IgG Ab 
responses  to  ragweed  AgE  were  determined  by  a  similar  RIA  using  a  highly  purified  AgE 
preparation, as described in detail elsewherefl Intradermal and puncture skin test procedures 
were  performed  as  previously  described  (1).  Pretreatment  total  serum  IgE  levels  were  also 
available on all study patients (1). 
2 Marsh D. G., E. Ehrlich-Kautzky, and P. S. Norman. A kinetic study of human immune response to 
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HLA  Typing and Data Analysis.  HLA-A,B,C, and D  typings were available on all 61 study 
subjects and DR typings on 37 of these individuals (1). 
In analyzing IgG Ab responses to Ra5 and AgE after each year of therapy, we considered 
only the first 3 yr of therapy, where complete sets of sera were available on 40 patients (Table 
I). Our overall approach was similar to that used in the preceding study (1). In the nonpara- 
metric statistical analyses (using Fisher's exact test), IgG Ab responses were dichotomized as 
Ra5+  or  Ra5-.  In  analyzing log[IgG Ab]  responses  to  either Ra5  or AgE by parametric 
statistics, HLA type, log[pretreatment total IgE], age, sex, and previous immunotherapy (before 
this study) were categorized as previously described (1).  In addition, "type of current immu- 
notherapy" and log[antigen dose] were included as further independent variables. In view of 
the different lengths of treatment during each year (preseasonal vs. perennial), the "final doses" 
administered ~2 wk before the post-treatment serum sample, rather than cumulative yearly 
dosages,  were  used  in  computing  the  log[Ra5]  and  log[AgE]  equivalent  doses.  With  few 
exceptions, the final doses were also the largest single doses administered in any given year. 
Results 
IgG Ab Responses.  Fig.  1 illustrates the changes in serum IgO Ab responses to Ra5 
in  14  immunized  individuals who were categorized as Ra5+  both  by skin test  and 
IgE  Ab before  therapy  (1).  All had  significant  levels of IgG Ab  before  treatment. 
Subsequent IgG Ab responses in the 13 Dw2+ subjects (shown by solid lines) and one 
Dw2-  subject  (J,  Ko.;  dashed  line  in  Fig  1 a)  were  similar.  In  the  preseasonal 
treatment  group  (N  ~- 9),  the IgG Ab levels rose significantly after the first period 
(year  1)  of  12-16  wk of treatment,  fell between  years  1 and  2,  when  therapy  was 
discontinued, and rose again when therapy was recommenced in year 2. There was a 
subsequent decrease followed by an increase in IgG Ab levels during years 2-3. In the 
case of the five patients receiving perennial therapy, all subjects except M.  K., who 
received a  very low dosage of ragweed allergen during the  1st yr (cumulative dose, 
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Fro.  1.  IgG Ab responses to Ra5 in all patients who were phenotypically Ra5+ by IgE Ah and 
skin test before therapy with ragweed. (a) Ra5+, preseasonal Rx;  Co) Ra5+, perennial  Rx. Each 
patient is designated by his initials and a symbol that also indicates the type of antigen used. Several 
patients switched treatment (e.g., from allergen to allergoid), indicated by a change in the shading 
of the patient's symbol. The number of years of treatment  is given in parentheses after the patient's 
initials in the case of perennial therapy (Fig. 1  b). MARSH ET AL.  1455 
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Flo.  2.  ]gG Ab responses to Ra5 in patients who were phenotypically Ra5- by IgE Ab and skin 
test before therapy with ragweed. (a) Ra5-, preseasonal Rx; (b) Ra5-, perennial Rx. In the case 
of nonresponders, the number of patients in each treatment  category is indicated. See Fig. 1 for 
further description of symbols. Individuals typing DR2+,Dw2- were J. B., W. E., C. Li., and C. S. 
0.06/~g Ra5;  final dose, 0.01 #g Ra5) showed about a  10- to  100-fold rise in IgG Ab 
level during the 1st yr of therapy. Throughout the whole period of perennial therapy, 
patients other than M. K. maintained  Ab levels of 1,000-10,000 ng/ml, which is the 
range of peak responses achieved by most subjects treated preseasonally, a 
Fig.  2  shows the IgG Ab responses to Ra5  after preseasonal  or perennial  therapy 
with  ragweed  for 47 individuals  who had  no IgE Ab and were skin test  negative to 
Ra5  before  therapy  (although  three  individuals,  M.  S.,  E.  O.,  and  W.  R.,  had 
detectable  IgG Ab before treatment).  All 9  Dw2+ individuals as well as  10 (26%)  of 
Dw2-  individuals  made  substantial  IgG  Ab  responses  to  Ra5  within  2  yr  after 
receiving either preseasonal or perennial therapy. All of the remaining 28 Ra5-,Dw2- 
subjects  except  one  showed  no  detectable  IgG Ab  response  throughout  the  entire 
treatment period (averaging 4 yr). The one exceptional subject (C. Li.; Fig. 2 a) made 
trace IgG Ab responses (<10 ng/ml) detectable at years 4-9. 4 In the case of one Dw2+ 
individual  (M.  Ke.), who received quite low therapeutic  dosages  (final dose, 0.06 #g 
Ra5),  no response was observed after year  1 of preseasonal  therapy,  but  an IgG Ab 
response was observed at year 2, as dosages were increased. 
In summary, after  1-2 yr of therapy, all 22 Dw2+ subjects  (13 RaS+ and 9 Ra5- 
by pretreatment  IgE Ab)  made detectable  IgG Ab responses to Ra5, whereas of 39 
Dw2-  subjects, only 11 subjects  (1  Ra5+ and  10 Ra5-)  responded similarly. 
Univariate  Analyses.  Table  II  presents  the  results  of analyses  of serum  IgG  Ab 
responses to Ra5 at years 0-3 for all treated subjects (group A) and subjects who were 
phenotypically Ra5-  by skin test  and IgE Ab before therapy  (group B). Individuals 
within  these two groups were classified  as  Ra5  IgG Ab+ or Ra5  IgG Ab-  at  each 
year,  according  to  whether  or  not  they  made  a  detectable  IgG  Ab  response  (>3 
3 Peak IgG Ab levels toward AgE were also in this concentration range for most patients. 
4 The significance of these persistent low levels is questionable in view of the failure of the response to 
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TABLE  II 
Associations  between HLA-B7 and Dw2 and IgG Ab Responses  to Ra5 for All Available Treated Patients 
(Nonparametric  Statistics) * 
Number of 
subjects with  Percent  with  Percent with  Rel-  Rela-  IgG Ab  B7  P val-  Dw2  ative  P values  tive  phenotype  ues  risks  risks 
Ra5+  Ra5-  Ra5+  Ra5-  Ra5+  Ra5- 
Group A, all treated subjects 
Year 0 (N =  61)  17  44  53  23  0.032  3.8  82  18  <0.0001  21 
Year 1 (N =  61)  28  33  50  15  0.008  5.6  75  3  <0.0001  96 
Year 2 (N -- 50)  26  24  46  13  0.014  6.0  62  0  <0.0001  77:[: 
Year 3 (N = 40)  23  17  43  12  0.041  5.8  57  0  0.0001  45:~ 
Group B, subjects who were phenotypically Ra5- by skin test and IgE Ab before therapy 
Year 0 (N = 47)  3§  44  33  23  NS][  1.7  33  18  NS  2 
Year 1 (N =  47)  14  33  43  15  NS  4.2  57  3  0.000l  43 
Year 2 (N =  42)  18  24  33  13  NS  3.5  44  0  0.0004  40~ 
Year 3 (N =  34)  17  17  29  12  NS  3.1  41  0  0.0072  25:~ 
* Other associations: negative associations  with A1 at year 3 in group B (P -  0.03) and with B15 at years  1 
and 2 in group A (P = 0.05 and 0.007, respectively). 
:~ Determined by the Haldane formula (1, 8) because no Ra5- subjects were Dw2+. 
§ Before therapy, low levels of IgG Ab to Ra5 (4 and 7 ng/ml) were detected in two Dw2- subjects and a 
somewhat  higher level (34 ng/ml) in a Dw2+ subject,  all of whom had no detectable IgE Ab and were 
skin test negative.  These three subjects  in group B, along with  14 Ra5 IgE Ab+,IgG Ab+ individuals, 
constitute the 17 Ra5+ subjects in group A. 
[1 Not significant. 
ng/ml)  (1),  and  the data  were analyzed  by  Fisher's exact  test.  The  analyses  showed 
striking associations  between Dw2 and  presence of IgG Ab to Ra5  for both groups A 
and  B.  Less  striking  associations  were  observed  between  IgG  Ab  responses  and  B7, 
none of which  was significant  in group  B. Two other specificities (A1  and  B15)  were 
significantly associated  with IgG Ab response  in one or two analyses  (see footnote to 
Table  II).  These  latter  associations  were  weak  and  sporadic  and  are  probably  not 
important  in view of the large number  of analyses performed. 
We next compared  the geometric mean IgG Ab responses to Ra5  during the first  3 
yr  of  treatment  for  three  subgroups  of  patients  (Ra5+,Dw2+;  Ra5-,Dw2+; 
Ra5-,Dw2-),  where  the  Ra5  response  phenotypes  were based  on  IgE Ab  responses 
before therapy  (Fig. 3). To maintain  consistency within the year to year comparisons, 
only the 40 subjects  who remained on treatment  for 3  yr were included.  Comparison 
of the  geometric  mean  IgG  Ab  responses  in  the  Ra5+,Dw2+  vs.  the  Ra5-,Dw2+ 
group showed  that  the difference in  IgG Ab at year 0  remained significant  at year  1. 
The  difference was,  however,  much  less marked  and  no  longer significant  at  years  2 
and  3. After only  1 yr of therapy, the geometric mean IgG Ab response  to Ra5  for the 
group  that  had  been  phenotypically  Ra5-,Dw2-  before  therapy  was  significantly 
lower  than  the  Ra5-,Dw2+  group.  Furthermore,  the  geometric  mean  difference 
between  these two  groups  increased  from  7-fold at  year  1 to  over 50-fold by  years  2 
and  3. 
Among  the 27 Ra5-,Dw2-  subjects,  17 were nonresponders;  but the remaining  10 
individuals  made  quite good IgG Ab responses  after therapy  (Fig.  2).  The  geometric 
mean  IgG Ab levels in these  10 subjects  after each year of therapy  for years  1,  2, and MARSH ET AL.  1457 
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3 were compared against  the corresponding geometric mean Ab levels  in the seven 
Ra5-,Dw2+ subjects. As therapy proceeded, an increasingly greater differential Ab 
response  was  observed  in  the  Ra5-,Dw2+  group.  The  difference  between  the 
Ra5-,Dw2+ and  Ra5-,Dw2-  groups was significant by year 3  (geometric means, 
623 vs.  107 ng/ml, respectively; P  =  0.01). 
Multivariate Analyses.  We wished to compare both the degree and significance of 
the association  between  HLA type  (and  other independent  variables)  and  IgO Ab 
responses  to  Ra5.  This  was  done  by  multiple  regression  analysis  in  which  the 
individual  HLA specificities, log[pre-treatment total IgE], age, sex,  previous immu- 
notherapy,  type  of therapy,  and  log[Ra5  dose]  were  independent  variables,  and 
log[IgG Ab] was the dependent variable. First, we carried out three stepwise multiple 
regressions in which post-treatment IgG Ab data for all available patients at years 1, 
2, and 3 were included, except for a  few individuals treated with alum-precipitated 
ragweed, for whom antigen dosage was not known precisely. The analyses revealed 
extremely striking associations between  Dw2  and  log[IgG Ab]  at  years  1,  2,  and  3 
(P  <  10  -1°  in  all  cases).  In  addition,  previous  immunotherapy  was  significantly 
positively associated with log[IgG Ab] at year 1 (P =  0.01)  but not at years 2 and 3. 
Further significant associations were observed in one or two of the analyses with A2, 
A9, B12, B13, B14, B17, B27, Cw2, and Dwl, of which A2, B14, B27, and Cw2 were 
negatively associated.  These associations were generally weak and showed no clear 
pattern throughout the 3 yr of therapy, except for positive associations with B13 at 
years 2 and 3  (P--< 0.001  in both cases)  and negative associations with A2 at year 2 
(P =  0.005)  and year 3 (P -- 0.002). Antigen dosage was not significantly correlated 
with  log[IgG Ab] to Ra5 either in the whole study group or the subset of Ra5 IgE 
Ab+ subjects. 
We wished to examine critically the relative influence of each of the variables found 1458  Dw2 AND RESPONSE  TO  Ra5  AFTER IMMUNOTHERAPY 
TABLE III 
Multiple Regression Analyses: Significant Associations between HLA and Log[lgG]  Ab Response to Ra5 
after Ragweed Immunotherapy of 40 Patients * 
Variable 
Period of therapy with ragweed 
Year 0  Year 1  Year 2  Year 3 
Dw2§  b~  0.595  0.784  0.823  0.874 
P(two-tail)  1.2 ×  10  .4  2.9 ×  10  .8  1.4 ×  10  -8  9.4 x  10  l0 
B  1311  b~:  -0.156  -0.010  0.248  0.272 
Pp(two-tail)  0.24  0.92  0.022  0.008 
* Only variables found  to be significantly associated with  log[IgG Ab] to Ra5 from previous stepwise 
multiple regressions  were included in these analyses. These were: Dw2 (from year 0, 1, 2, and 3 analyses); 
A2 (from year 0, 2, and 3 analyses); previous immunotherapy and B14 (from year 0 and 1 analyses); B13 
(from year 2 and 3 analyses) and A9, B5, B12, B17, B27, Bw35, Cw2, Cw3, and Dwl  (significantly 
associated in just one of the previous analyses). Besides the cited associations, Bw35 was significantly 
associated at year 0 (b ffi 0.291, P ffi 0.040). 
~: Standardized regression coefficient. 
§ 13 people had the Dw2 phenotype. The proportions of IgG Ab+ subjects among these Dw2+ individuals 
at years 0, 1, 2, and 3 were 46%, 92%, 100%, and 100%, respectively. 
tl Eight people had the B  13 pbenotype. The proportions of IgG Ab+ subjects among these B I3+ individuals 
at years 0, 1, 2, and 3 were 25%, 63%, 75%, and 75%, respectively. 
to  be  significantly associated with  IgG Ab  response  to  Ra5  in  one  or more  of the 
previous stepwise regressions, namely, analysis of pretreatment  (year 0)  data on  all 
clinic patients (Table II in ref.  1) and the analyses of year  1, 2, and 3 data described 
above. Therefore, we carried out a series of multiple regression analyses in which only 
these  variables  5 were  included  in  analyses  of year  0,  1,  2,  and  3  data  for  the  40 
individuals who  had  been  on  ragweed  therapy  over a  3-yr period,  as  described  in 
Table I. 
The results of these analyses (Table III) showed that Dw2 and B 13 were significantly 
associated with log[IgG Ab] to Ra5. These two associations had previously shown the 
greatest  significance in  the  stepwise  regressions.  (Bw35  was  also  weakly associated 
with  log[IgG Ab], but  only  at  year 0;  see  footnote  to  Table  III). The  associations 
between log[IgG Ab] to Ra5 and Dw2 were particularly striking; they progressively 
increased  between  years  0  and  3,  both  in  strength  and  significance,  indicated  by 
changes  in the standardized regression coefficient b  and P  values.  By year 3,  the b 
value had  reached  0.874  (for the range  of -1  to  +1),  with  a  P  value of 10 -9.  The 
associations between log[IgG Ab] and HLA-B13 were not significant at years 0  and 
1 but  were  significant by years 2  and  3.  These  trends  toward  stronger associations 
between IgG response and Dw2 and B 13 as therapy proceeded were also reflected in 
the  increased  proportions  of responders  among  Dw2+  and  B13+  individuals  (see 
footnotes to Table III). It is also of interest to note that two of the three patients who 
had IgG Ab but no IgE Ab before treatment  (M.  S. and L. O.) were B13+,  Dw2-; 
the other similar individual (W. R.) was B13-, Dw2+. 
IgE Ab Responses  after  Therapy.  We have seen that  IgG Ab responses to Ra5 were 
induced in certain genetically predisposed individuals after ragweed immunotherapy. 
Next, we wished to evaluate the possibility that  therapy might  also induce  IgE Ab 
responses (detectable by RIA and skin testing) in some subjects. 
Definitive IgE Ab responses were seen only in the  14 subjects who were sensitive to 
The variables included are cited in a footnote to Table lII. MARSH  ET  AL.  1459 
Ra5 before therapy and in one Ra5-,Dw2+  subject  (W. R.;  Fig.  2b). After 5 yr of 
therapy, patient W. R. had an intradermal skin test end point (8- to  10-mm wheal) 
at  10  -6 #g Ra5/ml, and his serum contained ~430 ng IgE Ab/ml. The IgE Ab level 
could not be measured accurately because of the extremely high IgG Ab level (11,500 
ng/ml). This individual was exceptional in that he had quite substantial pretreatment 
IgG Ab  (34 ng/ml) and had the highest total IgE level (5,390 ng/ml) of anyone on 
the study. An additional Ra5-,Dw2+  subject  (C.  M.; Fig. 2 a), who had the second 
highest IgE level (468 ng/ml) among Ra5-,Dw2+ subjects, became significantly skin 
test positive (8- to 10-mm wheal at  10  -3 #g Ra5/ml by intradermal test) after 3 yr of 
therapy, although his serum contained no detectable IgE Ab to Ra5. 
DR-D Relationships.  The relationship between IgG Ab  response to Ra5  and  DR 
phenotype was studied in 37 of the 61  study subjects, including  15 of the Ra5 IgE 
Ab-  subjects  who produced  IgG  Ab  after therapy.  Among  RaS-,Dw2-  subjects 
(pretreatment), we wished to investigate whether there was a  greater prevalence of 
DR2 in people who made substantial IgG Ab responses vs. those who did not. In fact, 
there was no significant difference in the proportion of DR2 in these two Ra5-,Dw2- 
subgroups (2 of 10 responders vs. 2 of 7 nonresponders had DR2). As previously stated 
(1), there was  a  perfect concordance between DR2  and  Dw2  in all  Ra5  IgE Ab+ 
subjects, all of whom made good IgG Ab responses after therapy. 
Are the IgG Ab Responses to Ra5 Antigen  Selective?  The question arose as to whether 
the IgG Ab responses to Ra5 seen in certain previously Ra5-  subjects might be an 
Ra5-selective phenomenon or simply reflect an overall hyperresponsiveness to ragweed 
antigens in general. To test this possibility, we analyzed IgG Ab response to ragweed 
AgE,  which  is  known  to  be  a  good  immunologic  parameter  of response  toward 
ragweed therapy (3). The geometric mean post-treatment anti-AgE IgG Ab levels at 
years 1, 2, and 3 were compared by t test in Ra5+ vs. Ra5- subjects (IgE or IgG Ab 
phenotypes before therapy). At years  1 and 3, there was no significant difference in 
the geometric mean IgG Ab to AgE between the Ra5+ and Ra5-  groups. This was 
true whether pretreatment response to Ra5 was classified by IgE or IsG Ab (P >  0.4 
in all cases). At year 2, the responses to AgE were actually greater in Ra5 IgE Ab- 
than Ra5 IgE Ab+ individuals (geometric means, 3,300 vs.  1,010 ng/ml; P <  0.001) 
and in Ra5 IgG Ab+ vs. Ra5 IgG Ab-  subjects (P =  0.003). These results strongly 
suggest  that  IgG Ab  responses  to  Ra5  do not  merely reflect a  generalized hyper- 
responsiveness toward ragweed antigens. 
Discussion 
Artificial  immunization  with  ragweed  antigens  in  much  higher  dosages  than 
encountered by natural exposure to pollen induced IgG Ab responses to Ra5 only in 
certain  ragweed-allergic  patients.  Both  the  quantitative  and  qualitative  degree of 
response to Ra5 were significantly associated with HLA-Dw2 throughout treatment 
(P <  0.0001  for all comparisons). By multiple regression analysis, both the strength 
and significance of the relationship between Dw2 and log[IgG Ab] response to Ra5 
were found to increase throughout a  3-yr period of therapy, reaching a  significance 
level of 10  -9 after the 3rd yr. Immunotherapy did not induce measurable levels of IgE 
Ab to Ra5 in previously Ra5-insensitive subjects except in one Dw2+ person (~r. R.), 
who had a modest amount of IgG Ab before therapy and a very high total IgE level, 
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These findings are striking, especially in view of the heterogeneity in the type of 
antigen, antigen dosage, and dosage regimen used in the patients (Table I). However, 
the cumulative annual  immunotherapeutic dosages  of Ra5  are still  very low on a 
body-weight basis in comparison with the "low" doses of protein antigens normally 
used for immunogenetic studies of H-2 linkage in mice (9, 10). The respective dosages 
average ~0.01-0.3/~g/kg for 75 kg adult humans (Table I) vs.  10-100 #g/kg for mice 
(two 0.1-/~g or  1.0-#g  doses  of antigen  on  alumina  adjuvant).  By comparison,  the 
dosages of inhaled  Ra5  are no more than  ~0.001  #g/kg  per yr for adult  humans 
living in  the  Baltimore area  (4).  These dosage differences should  be considered in 
extrapolating from animal  models  to our data  in  humans.  As  noted  by Provoust- 
Danon et al. (11), there is clearly a need for further studies of the influence of antigen 
dosage on the genetics of immune response in animals. The effect of adjuvants and 
route of immunization are further factors to be considered. 
We also  found that  IgG Ab  response to Ra5  in  man appears  to be an antigen- 
selective effect. The level of IgG Ab  response to the highly immunogenic ragweed 
allergen, AgE (toward which all subjects responded well), was not significantly related 
to IgG Ab response to Ra5. Indeed, there was some evidence for a negative relation- 
ship. 
There are several possible genetic hypotheses that can be invoked to explain these 
data, including (a) that HLA-Dw2 might be the major Ir-Ra5 gene in Caucasians;  (b) 
there is a separate Ir-Ra5 gene in linkage disequilibrium with HLA-Dw2 that results 
in the association between Dw2 and response to Ra5 seen in Caucasian populations; 
(c) there is an Ir-Ra5'  gene somewhere in the genome (not necessarily HLA-linked) 
that interacts with, or is dependent on, HLA-Dw2 for the expression of response to 
Ra5. 
Analogous  hypotheses to  (a)  and  (b),  particularly the  latter,  have  been  popular 
explanations  for disease-association  data  and  have been extensively discussed else- 
where (12,  13). In guinea pig and mouse experiments, monospecific sera raised against 
Ia  antigens  (which  include  the  analogues  of human  DR)  block Ir-gene controlled 
responses in vitro (14-16). These experiments, together with immunochemical analyses 
of complementing E~ and E~ genes that  map  in  the I-E and I-A  regions of mouse 
H-2 (17,  18), suggest an identity between H-2-1inked/r-gene products and Ia antigens 
(16).  In the light of these findings, a reasonable interpretation is that DR2 or a gene 
closely linked to and in strong linkage disequilibrium with DR2 is the Ir-Ra5 gene. 
One  might  further  hypothesize  that  this  gene  codes  for  a  cell  receptor  for  an 
immunodominant determinant on Ra5. If DR2 itself was such a receptor, DR2 rather 
than Dw2 might be expected to show the more striking association with response to 
Ra5; in fact, the converse is the case. Perhaps the most probable explanation is that 
anti-DR2 typing sera recognize a broader range of D specificities than those recognized 
by Dw2  homozygous typing cells, the latter corresponding more specifically to the 
product of Ir-Ra5. 
As an alternative, we feel that explanations based on the third hypothesis deserve 
serious consideration. One must explain why, on the one hand, only a proportion of 
Dw2+ subjects respond after natural exposure to extremely limiting doses of inhaled 
Ra5, whereas, on the other hand, all Dw2+ ragweed-allergic subjects make good IgG 
Ab responses after injection of much higher (but still immunogenically limiting) doses 
of Ra5.  Among Westinghouse subjects  (most of whom had never received immuno- MARSH ET AL.  1461 
therapy), only  10 of 29  (34%)  of Dw2+  ragweed-allergic subjects and only  1 of 50 
(2%) of Dw2+ subjects in the nonragweed-allergic group made IgG and/or IgE Ab 
responses  to  Ra5  (1).  Nongenetic  factors  (especially  antigen  exposure)  and  IgE- 
regulating gene(s) must certainly play important roles in determining this differential 
responsiveness (19).  On  the other hand,  it seems unlikely that  these factors are the 
only determinants among Westinghouse ragweed-allergic subjects, who were selected 
for their relatively uniform exposure to ragweed pollen (20). 
We believe that our observations suggest the possibility that another gene (Ir-Ra5), 
apart from Dw2, may code for a cell receptor facilitating response to the immunodom- 
inant  determinant on Ra5. This receptor could be the controversial T  cell receptor 
believed to be encoded by Ig heavy-chain genes (16,  21), or it could be expressed on 
antigen-presenting ceils along with the product of the Dw2 (Ir-Ra5)  gene. In either 
case, the postulated product of the Ir-Ra5' gene may have affinities for both Ra5 and 
Ir-Ra5. According to this general postulate, an individual would require two genes, 
Ir-Ra5 and Ir-Ra5', to produce IgG Ab (and usually IgE Ab) to Ra5 merely as a result 
of natural  exposure to  ragweed  pollen.  Individuals  having Ir-Ra5 but  not  Ir-Ra5' 
would require the higher antigenic dosages achieved by artificial  immunization  to 
respond. Individuals possessing neither Ir-Ra5 nor Ir-Ra5' would usually not respond 
to  Ra5,  even  after  high-dose  immunotherapy  (see  below  for  discussion  of other 
possibilities). 
The third hypothesis allows for the possibility that the postulated Ir-Ra5' gene is 
not linked to the HLA complex, a result that is entirely consistent with data from our 
family studies (22). Among families selected on the basis of an Ra5-allergic propositus, 
other  family members  (including  those  who  are  ragweed-allergic)  usually  do  not 
respond to Ra5, even though they possess the same Dw2-containing haplotype as the 
propositus  (22,  and  unpublished  observations).  From the  data presented here, one 
would expect that  such  individuals would  respond after ragweed  immunotherapy. 
Indeed, such an experiment might be expected to yield data entirely consistent with 
immunogenetic experiments in laboratory animals where the effect of MHC-linked 
genes is well established (16). 
We must also explain why certain Dw2- individuals respond to Ra5, including a 
sizable proportion who make moderate IgG Ab responses after artificial immunization. 
One possibility is that some of these people possess  Ir-Ra5', which may permit weak 
to moderate responses even when Dw2 (Ir-RaS) is absent. Alternatively, a  few of the 
Dw2- subjects, who develop IgE and IgG Ab responses as a result of natural exposure 
and/or respond well after immunotherapy, might well be able to recognize the Ra5 
molecule via a  secondary determinant(s)  or, perhaps, via the primary determinant 
with a lower affinity. There is some suggestion from the present studies that HLA-B13 
might be associated with a  gene conferring response to one such secondary determi- 
nant. 
In  conclusion,  our  results  re-emphasize  the  usefulness  of the  allergy  model  for 
investigations of the genetics of human immune response (19). It  is now clear that 
studies  of response  toward  the  higher  antigenic  dosages  administered  as  part  of 
accepted immunologic therapy of allergy add  important  new  information to data 
from studies of ultra-low dose natural exposure. It is particularly appropriate to use 
a low molecular weight allergen like Ra5 because the number ofimmunodeterminants 
is restricted. Also, the allergen should be ultra-pure because of the likelihood that a 1462  Dw2 AND RESPONSE TO Ra5 AFTER IMMUNOTHERAPY 
person's  response  to  impurities  might  be  interpreted  as  a  response  to  the  major 
component. The striking relationship between Dw2 and IgE and IgG Ab responses to 
Ra5  provides strong evidence for the role of an  HLA-D specificity in  determining 
immune response in outbred, highly polymorphic human populations. The variable 
expression of Dw2-associated response to Ra5 under different degrees of immunization 
suggests the involvement of a  further genetic locus, possibly unlinked to HLA. 
Summary 
After  artificial  immunization  (immunotherapy)  with  ragweed  antigens,  specific 
immunoglobulin G  (IgG) antibody (Ab) response to Ra5 was significantly associated 
with  HLA-Dw2  (P <  0.0001).  From  a  total  of 61  treated  patients,  all  22  Dw2+ 
subjects made good IgG Ab responses to Ra5 by year 2 of therapy (21 by year 1), even 
though 8 of them had no detectable IgG Ab and 9 had no detectable IgE Ab before 
therapy. The prevalence of IgG Ab response among 39 Dw2- subjects was markedly 
lower; only 11  (28%)  responded well after 1-9 yr of therapy. Both by univariate and 
multivariate statistical  analysis, Dw2 was also found  to be strongly associated with 
the quantity of IgG Ab produced. In particular, both the strength and significance of 
the association between Dw2 and log[IgG Ab] response to Ra5 increased over a  3-yr 
period  of ragweed  therapy  (P =  10  -9 by year 3).  Multiple  regression  analysis  also 
revealed a  weak association with HLA-B 13, which became apparent only after year 
2 of therapy. Genetic hypotheses for these findings are discussed.  In particular,  the 
possibility of a second Ir gene, Ir-Ra5', separate from HLA-Dw2 and possibly located 
elsewhere in the genome, is considered. 
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